AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Opthea Ltd

0.390

0.000

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:0.390

Open:0.390

Low:0.390

Close:0.390

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Opthea Ltd

Exchange:

ASX

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.opthea.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OPTOA.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPTOA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPTOA.AU\",,,,,undefined,":{"symbol":"OPTOA.AU","market":"AU","secType":"STK","nameCN":"Opthea Ltd","latestPrice":0.39,"timestamp":1749795120000,"preClose":0.39,"halted":0,"volume":0,"delay":0,"nameEN":"Opthea Ltd","floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":0,"latestTime":"06-13 16:12:00 AEST","open":0.39,"high":0.39,"low":0.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1750032000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.39,"openAndCloseTimeList":[[1749772800000,1749794400000]],"volumeRatio":0,"lotSize":0,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPTOA.AU\",,,,,undefined,":{"symbol":"OPTOA.AU","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0.39,"amplitude":0,"preClose":0.39,"low":0.39,"week52Low":0.18,"pbRate":"--","week52High":0.58,"institutionHeld":0,"latestPrice":0.39,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.39,"prevYearClose":0.3,"prevWeekClose":0.39,"prevMonthClose":0.39,"prevQuarterClose":0.39,"fiveDayClose":0.39,"twentyDayClose":0.39,"sixtyDayClose":0.39},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.opthea.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0.3},{"period":"1year","weight":0.56},{"period":"ytd","weight":0.3}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":0.0534},{"period":"3month","weight":0.0628},{"period":"6month","weight":0.1481},{"period":"1year","weight":0.2169},{"period":"ytd","weight":0.1564}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.","exchange":"ASX","name":"Opthea Ltd","nameEN":"Opthea Ltd"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OPTOA.AU\",market:\"AU\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPTOA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPTOA.AU\",market:\"AU\",,,undefined,":[]}}